Merck’s Keytruda gets biliary tract cancer approval, brings in more positive survival data in renal carcinoma

Mer­ck is kick­ing off No­vem­ber with two pos­i­tive re­sults for its an­ti-PD-1 ther­a­py Keytru­da — a win in a sec­ondary end­point of over­all sur­vival in re­nal cell car­ci­no­ma, and a com­bo ap­proval in bil­iary tract can­cer, al­so based on an over­all sur­vival end­point.

Mer­ck said on Wednes­day that Keytru­da is the first ther­a­py to show a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in over­all sur­vival as an ad­ju­vant ther­a­py in pa­tients with re­nal cell car­ci­no­ma who have a high risk of re­cur­rence fol­low­ing nephrec­to­my, the re­moval of one or both kid­neys.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.